ÂÜÀòÂÒÂ×

Rahul joined Polaris Partners in 2021 and serves as an entrepreneur partner. He is a biotech executive and physician-scientist, founding and building biotechnology companies as well as working as a practicing physician.

Most recently, Rahul was Chief Executive Officer at Pandion Therapeutics, a company focused on therapeutics for autoimmune and inflammatory diseases, which he led from Series A through its clinical transition, initial public offering, and its ultimate acquisition by Merck for $1.85B. Prior to joining Pandion, Rahul founded Corvidia Therapeutics, a precision cardiovascular company, where he served as Chief Medical Officer and Chief Strategy Officer. Corvidia Therapeutics was acquired by Novo Nordisk for $2.1B. Across his companies, Rahul has led fundraising totaling over $300M to date. Prior to Corvidia, Rahul served as a director in the Emerging Innovations Unit at AstraZeneca, where he was recognized with the AstraZeneca Leadership Recognition Award.